MEI Pharma Gets $27.5M In PIPE
San Diego-based MEI Pharma, a publicly traded developer of oncology drugs, said today that it has completed a $27.5M private placement. The new funding was led by Vivo Ventures and New Leaf Venture Partners. MEI Pharma said the new funding will go to advance clinical development of its lead drug candidate, which is an oral histone deacetylase (HDAC) inhibitor. That compound is being used to treat myelodysplastic syndrome (MDS), acute myeloid leukemia and myelofibrosis.
posted on Thursday, December 20, 2012 (Link to more information)

Related companies:
Meidlinger Partners

Related stories:
> IDM Pharma Gets $12.8 in PIPE
> Victory Pharma Acquired By Sciele Pharma
> Kite Pharma Names CFO
> Kite Pharma Scores $50M For Cancer Immunotherapy
> Kite Pharma Raises $15M Home